Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment - Buttiron Webber, Tania; Provinciali, Nicoletta; Musso, Marco; Ugolini, Martina; Boitano, Monica; Clavarezza, Matteo; D'Amico, Mauro; Defferrari, Carlotta; Gozza, Alberto; Briata, Irene Maria; Magnani, Monica; Paciolla, Fortuna; et al. (European journal of cancer (1990), 2021)
Keywords: Active control; Aged; Antibodies, Viral - blood; Antibody responses to the BNT162b2 vaccine; Biomarkers - blood; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - adverse effects; BNT162 Vaccine - immunology; Cancer; Cancer biological treatment; Cancer chemotherapy; Cancer hormone therapy; Cancer immunotherapy; Cancer target therapy; Cancer therapies; Cancer vaccines; Case-Control Studies; Cell number; Chemotherapy; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 vaccine in cancer patients; Endocrine therapy; Female; Humans; Immunization; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Immunosuppressive agents; Lymphocytes; Male; Middle Aged; mRNA; Neoplasms - diagnosis; Neoplasms - immunology; Neoplasms - therapy; Original Research; Patients; Prospective Studies; Risk Factors; Risk management; SARS-CoV-2 - immunology; SARS-CoV-2 - pathogenicity; SARS-CoV-2 vaccine; SARS-CoV-2 vaccine adverse effects; Seroconversion; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Surveillance; Time Factors; Treatment Outcome; Vaccination; Vaccination - adverse effects; Vaccine Efficacy; Vaccines; COVID-19 vaccine in cancer patients; SARS-CoV-2 vaccine adverse effects; Cancer chemotherapy; Immunogenicity; Cancer hormone therapy; SARS-CoV-2 vaccine; Antibody responses to the BNT162b2 vaccine; Cancer immunotherapy; Cancer target therapy; Cancer biological treatment